
    
      The primary objective of this study is to evaluate the efficacy of brodalumab, compared to
      placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the
      efficacy of brodalumab compared to placebo at week 16 and week 24. The safety objective of
      this study is to evaluate the safety profile of brodalumab in subjects with psoriatic
      arthritis.
    
  